10X1000-TECH
The Global Digital Talent Community 10x1000 Tech for Inclusion (“10x1000”) and FINOLAB, a Tokyo-based fintech office and business community, have entered into a collaborative effort to enhance digital capacity and drive digital economic growth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240305260615/en/
The Global Digital Talent Community 10x1000 Tech for Inclusion (“10x1000”) and FINOLAB have entered into a collaborative effort to enhance digital capacity and drive digital economic growth. (Photo: Business Wire)
Pursuant to a signed Memorandum of Understanding (MoU), FINOLAB will collaborate with 10x1000 to identify and invite qualified participants through its network of member institutions, partners, affiliates, and other stakeholders to participate in the learning programs provided by 10x1000. Participants will be afforded the opportunity to serve as both learners and industry experts.
Additionally, the two organizations will work together to develop learning content that highlights and promotes the digital landscape and opportunities in Japan and drive knowledge sharing through their respective networks.
The MoU was signed by Jennifer Tan, Program Head for 10x1000 Tech for Inclusion, and Makoto Shibata, Head of FINOLAB and Chief Community Officer at FINOLAB. The signing ceremony was witnessed by Sopnendu Mohanty, Chief Fintech Officer at the Monetary Authority of Singapore, Leiming Chen, Chief Sustainability Officer of Ant International and Senior Vice President at Ant Group, and Chie Ito, Chief Executive Officer of FINOLAB.
“We are honored to join hands with FINOLAB to extend the network of 10x1000 in terms of both learners and lecturers, which will benefit the community profoundly. This collaboration marks a pivotal moment in our journey towards cultivating a vibrant and inclusive talent development ecosystem, where innovation knows no boundaries,” said Ms. Tan.
“Our members would benefit immensely from the knowledge accumulation of 10x1000 and we may also be able to contribute our experiences in Japan to the 10x1000 community members. The collaboration would be an appropriate opportunity for all of us to appreciate the true value of open innovation,” commented Mr. Shibata.
By the year 2023, 10x1000 has certified a total of 6,243 learners from over 100 countries and regions. The Philippines, Indonesia, Thailand, Bangladesh, and Nigeria were the top five countries from which most learners came. Of the certified learners, females accounted for 49% of the total learner base. It is noteworthy that the certified learners represent more than 2,000 organizations, and nearly 80% of them are micro, small, or medium-sized enterprises (MSMEs).
About 10x1000 Tech for Inclusion
10x1000 Tech for Inclusion is an open and global learning community that enables learners to become drivers of digital economic growth. Its mission is to nurture and inspire at least 1,000 emerging talents and tech leaders each year for the next ten years. 10x1000 is a philanthropic initiative launched jointly by the International Finance Corporation (IFC), a member of the World Bank Group, and Alipay in 2018.
About FINOLAB
FINOLAB is a membership business community and an office space located in the heart of international financial district in Tokyo to promote FinTech ecosystem and open innovation. Launched in Feb. 2016 by Mitsubishi Estate and Dentsu Group as the first FinTech Center in Japan, it consists of stakeholders, including startups, corporates, and regulators.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305260615/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom